Home » Stocks » SNCA

Seneca Biopharma, Inc. (SNCA)

Stock Price: $0.600 USD -0.007 (-1.15%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $0.600 +0.000 (0.03%) Nov 27, 4:48 PM

Stock Price Chart

Key Info

Market Cap 10.38M
Revenue (ttm) 13,520
Net Income (ttm) -13.89M
Shares Out 17.30M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $0.600
Previous Close $0.607
Change ($) -0.007
Change (%) -1.15%
Day's Open 0.610
Day's Range 0.580 - 0.619
Day's Volume 258,842
52-Week Range 0.500 - 4.090

More Stats

Market Cap 10.38M
Enterprise Value n/a
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 17.30M
Float n/a
EPS (basic) -0.21
EPS (diluted) -0.21
FCF / Share -0.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 14,234
Short Ratio 0.05
Short % of Float n/a
Beta 1.68
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 767.56
PB Ratio 0.74
Revenue 13,520
Operating Income -8.41M
Net Income -13.89M
Free Cash Flow -8.88M
Net Cash 12.65M
Net Cash / Share 0.73
Gross Margin 113.86%
Operating Margin -62,233.93%
Profit Margin -102,704.00%
FCF Margin -65,676.63%
ROA -43.62%
ROE -131.21%
ROIC -4,501.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$520.00*
Low
520
Current: $0.600
High
520
Target: 520.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.020.260.260.020.010.020.110.410.390.73
Revenue Growth-94.08%0%1500.39%55.96%-44.69%-82.88%-73.02%4.37%-46.74%-
Gross Profit0.020.260.260.020.010.020.110.410.390.73
Operating Income-8.63-8.26-13.31-20.64-19.16-17.44-12.52-10.16-12.99-15.18
Net Income-8.35-4.92-15.67-21.07-20.90-22.63-19.83-10.12-12.52-18.39
Shares Outstanding2.200.650.650.420.350.330.280.220.190.17
Earnings Per Share-3.80-7.54-23.98-50.60-59.80-67.60-70.20-44.20-67.60-109.20
Operating Cash Flow-7.26-7.69-13.42-15.62-18.93-11.71-10.59-8.48-8.10-9.98
Capital Expenditures---0.01-0.10-0.18-0.21-0.13-0.04-0.20-0.33
Free Cash Flow-7.26-7.69-13.43-15.71-19.11-11.91-10.72-8.52-8.29-10.31
Cash & Equivalents5.115.7911.6720.1912.2327.5316.857.442.359.26
Total Debt0.410.22-3.717.938.799.11---
Net Cash / Debt4.705.5711.6716.494.3118.747.737.442.359.26
Assets6.587.6813.8822.6014.9529.8419.418.754.0910.59
Liabilities1.461.635.3711.279.9812.1211.001.782.432.74
Book Value5.136.058.5211.334.9717.728.426.971.667.85
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Seneca Biopharma, Inc.
Country United States
Employees 7
CEO Kenneth C. Carter

Stock Information

Ticker Symbol SNCA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SNCA

Description

Seneca Biopharma, a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been completed Phase II clinical trials for the treatment of major depressive disorder; and NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.